To hear about similar clinical trials, please enter your email below
Trial Title:
Cryoablation for Advanced and Refractory Desmoid Tumors
NCT ID:
NCT06113094
Condition:
Desmoid Tumors
Conditions: Official terms:
Fibromatosis, Aggressive
Conditions: Keywords:
Desmoid tumors
Fibromatosis
Invasive tumors
Radiotherapy
Cryoablation
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors
with no potential for metastasis. The incidence is approximately 2 to 4 per million per
year in the general population. The "watch and wait" policy is the standard of care for
newly diagnosed patients in Europe. Patients who progress have first-line medical
treatment, surgery is no longer the treatment because there is a high rate of recurrence
(> 60%) and radiotherapy is not very suitable because the patients are often young and
the tumors are large. Cryoablation seems to be an effective therapeutic option that
should be evaluated.
Criteria for eligibility:
Study pop:
Adult patient (≥18 years old) having undergone cryoablation for an advanced desmoid tumor
refractory to medical treatment
Sampling method:
Non-Probability Sample
Criteria:
Inclusion criteria:
- Adult patient (≥18 years old)
- Having undergone cryoablation for an advanced desmoid tumor refractory to medical
treatment
- Having not expressed their opposition, after being informed, to the reuse of their
data for the purposes of this research.
Exclusion criteria:
- Subject who expressed their opposition to participating in the study
- Patient already included in another ongoing study
- Subject under guardianship or curatorship
- Subject under safeguard of justice
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Service d'Imagerie Interventionnelle - CHU de Strasbourg - France
Address:
City:
Strasbourg
Zip:
67091
Country:
France
Status:
Recruiting
Contact:
Last name:
Pierre AULOGE, MD
Phone:
33 3 69 55 15 26
Email:
pierre.auloge@chru-strasbourg.fr
Investigator:
Last name:
Pierre AULOGE, MD
Email:
Principal Investigator
Investigator:
Last name:
Afshin GANGI, MD, PhD
Email:
Sub-Investigator
Investigator:
Last name:
Roberto Luigi CAZZATO, MD
Email:
Sub-Investigator
Investigator:
Last name:
Julien GARNON, MD
Email:
Sub-Investigator
Investigator:
Last name:
François SEVERAC, Statistician
Email:
Sub-Investigator
Start date:
July 7, 2020
Completion date:
December 31, 2023
Lead sponsor:
Agency:
University Hospital, Strasbourg, France
Agency class:
Other
Source:
University Hospital, Strasbourg, France
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06113094
